Cancer Stem Cell News Volume 11.06 | Feb 16 2022


    2022-02-16 | CSCN 11.06

    Cancer Stem Cell News by STEMCELL Technologies
    Vol. 11.06 – 16 February, 2022

    Fusobacterium nucleatum Promotes Colorectal Cancer Cell to Acquire Stem Cell-Like Features by Manipulating Lipid Droplet-Mediated Numb Degradation

    The authors showed that Fusobacterium nucleatum promoted colorectal cancer stem-like cells (CCSCs) self-renewal, and non-CCSCs to acquire CCSC features by manipulating cellular lipid accumulation.
    [Advanced Science]

    Full Article

    Survey results on the needs and challenges in the human pluripotent stem cell field
    PUBLICATIONSRanked by the impact factor of the journal

    Protein C Receptor Maintains Cancer Stem Cell Properties via Activating Lipid Synthesis in Nasopharyngeal Carcinoma

    Researchers uncovered a subpopulation of cells labeled as CD45EPCAM+PROCR+ in nasopharyngeal carcinoma biopsy samples that exhibited stem cell-like characteristics.
    [Signal Transduction and Targeted Therapy]

    Full Article

    ADAR1-Mediated RNA Editing Links Ganglioside Catabolism to Glioblastoma Stem Cell Maintenance

    Scientists interrogated the role of adenosine-to-Inosine RNA editing mediated by adenosine deaminase acting on RNA1 (ADAR1) in glioblastoma stem cells and found that both ADAR1 and global RNA editomes were elevated in glioblastoma stem cell compared to normal neural stem cells.
    [Journal of Clinical Investigation]

    Full ArticleGraphical Abstract

    Regulation of Reverse Electron Transfer at Mitochondrial Complex I by Unconventional Notch Action in Cancer Stem Cells

    Researchers showed that reverse electron transfer through respiratory chain complex I was particularly active in brain cancer stem cells.
    [Developmental Cell]


    IFIT2-Depleted Metastatic Oral Squamous Cell Carcinoma Cells Induce Muscle Atrophy and Cancer Cachexia in Mice

    Genetically engineered and xenograft tumor models were used to explore the effect of interferon-induced protein with tetratricopeptide repeat 2 (IFIT2) -depleted metastatic oral squamous cell carcinoma on cancer cachexia.
    [Journal of Cachexia Sarcopenia and Muscle]

    Full Article

    NEDD4 Degrades TUSC2 to Promote Glioblastoma Progression

    Scientists reported that tumor suppressor candidate 2 (TUSC2) protein expression was reduced/lost in glioblastoma compared to normal brain due to protein destabilization.
    [Cancer Letters]


    A Novel CD34-Specific T Cell Engager Efficiently Depletes Acute Myeloid Leukemia and Leukemic Stem Cells In Vitro and In Vivo

    Researchers designed a CD34/CD3 bispecific T-cell engager (BiTE) and characterized its anti-leukemia potential in vitro, ex vivo and in vivo.


    Extracellular Microparticles Derived from Hepatic Progenitor Cells Deliver a Death Signal to Hepatoma-Initiating Cells

    The authors isolated extracellular microparticles derived from apoptotic hepatic progenitor cells and tested their ability to inhibit hepatocarcinogenesis.
    [Journal of Nanobiotechnology]

    Full ArticleGraphical Abstract

    Cold Atmospheric Plasma Differentially Affects Cell Renewal and Differentiation of Stem Cells and APC-Deficient-Derived Tumor Cells in Intestinal Organoids

    Scientists addressed the relevance of 3D organoid technology to investigate the biological effects of cold atmospheric plasma on normal epithelial stem cells and tumor cells isolated from mouse small intestine.
    [Cell Death Discovery]

    Full Article

    Explore tools and resources for your return to the lab

    Combination Therapy for Pancreatic Cancer: Anti-PD-(L)1-Based Strategy

    The authors highlight potential adverse effects of accumulative combination, and further point out future direction in optimization of combination, including targeting post-translational modification of PD-(L)1 and improving precision of treatment.
    [Journal of Experimental & Clinical Cancer Research]

    Full Article


    BriaCell Appoints Renowned Oncologist, Giuseppe Del Priore, MD, MPH, as Chief Medical Officer

    BriaCell Therapeutics Corp. announced the appointment of Giuseppe Del Priore, MD, MPH, as the Company’s Chief Medical Officer.
    [BriaCell Therapeutics, Corp.]

    Press Release


    Sy-Stem 2022

    March 20 – March 25
    Vienna, Austria

    > See All Events


    Postdoctoral Fellow – Cancer Biology

    Icahn School of Medicine at Mount Sinai – New York, New York, United States

    Postdoctoral Research Scientist – Immunology

    Babraham Institute – Babraham, Cambridgeshire, United Kingdom

    Postdoctoral Fellow – Cancer Immune Biomarkers

    Albert Einstein College of Medicine – Bronx, New York, United States

    Postdoctoral Fellow – Lung Carcinogenesis

    Albert Einstein College of Medicine – Bronx, New York, United States

    Postdoctoral Scholar – Tumor Immunology

    Moffit Cancer Center – Tampa Bay, Florida, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Cancer Stem Cell News Twitter